145 related articles for article (PubMed ID: 16937114)
1. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
Lutterbuese P; Brischwein K; Hofmeister R; Crommer S; Lorenczewski G; Petersen L; Lippold S; da Silva A; Locher M; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2007 Apr; 56(4):459-68. PubMed ID: 16937114
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
Schmidt M; Scheulen ME; Dittrich C; Obrist P; Marschner N; Dirix L; Schmidt M; Rüttinger D; Schuler M; Reinhardt C; Awada A
Ann Oncol; 2010 Feb; 21(2):275-282. PubMed ID: 19633042
[TBL] [Abstract][Full Text] [Related]
3. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
[TBL] [Abstract][Full Text] [Related]
4. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
6. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
Münz M; Murr A; Kvesic M; Rau D; Mangold S; Pflanz S; Lumsden J; Volkland J; Fagerberg J; Riethmüller G; Rüttinger D; Kufer P; Baeuerle PA; Raum T
Cancer Cell Int; 2010 Nov; 10():44. PubMed ID: 21044305
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Naundorf S; Preithner S; Mayer P; Lippold S; Wolf A; Hanakam F; Fichtner I; Kufer P; Raum T; Riethmüller G; Baeuerle PA; Dreier T
Int J Cancer; 2002 Jul; 100(1):101-10. PubMed ID: 12115595
[TBL] [Abstract][Full Text] [Related]
8. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
[TBL] [Abstract][Full Text] [Related]
9. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.
Prang N; Preithner S; Brischwein K; Göster P; Wöppel A; Müller J; Steiger C; Peters M; Baeuerle PA; da Silva AJ
Br J Cancer; 2005 Jan; 92(2):342-9. PubMed ID: 15655555
[TBL] [Abstract][Full Text] [Related]
10. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
Kurtz JE; Dufour P
Expert Opin Biol Ther; 2010 Jun; 10(6):951-8. PubMed ID: 20426706
[TBL] [Abstract][Full Text] [Related]
11. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
14. Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.
Kirman I; Whelan RL
Curr Opin Mol Ther; 2007 Apr; 9(2):190-6. PubMed ID: 17458174
[TBL] [Abstract][Full Text] [Related]
15. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
[TBL] [Abstract][Full Text] [Related]
17. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
Schmidt M; Rüttinger D; Sebastian M; Hanusch CA; Marschner N; Baeuerle PA; Wolf A; Göppel G; Oruzio D; Schlimok G; Steger GG; Wolf C; Eiermann W; Lang A; Schuler M
Ann Oncol; 2012 Sep; 23(9):2306-2313. PubMed ID: 22357251
[TBL] [Abstract][Full Text] [Related]
18. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.
Oberneder R; Weckermann D; Ebner B; Quadt C; Kirchinger P; Raum T; Locher M; Prang N; Baeuerle PA; Leo E
Eur J Cancer; 2006 Oct; 42(15):2530-8. PubMed ID: 16930989
[TBL] [Abstract][Full Text] [Related]
19. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
20. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
